Immunity Inflammation and Disease · 2024 · 11 citations · 33 references
Life SciencesImmunologyInternal MedicineAutoimmunityImmunopathologyRheumatologyAutoantibodiesAutoantibody-mediated DiseaseAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune Rheumatic DiseasesSystemic Autoimmune DiseaseAnti-neutrophil Cytoplasmic AntibodiesAntibodiesAntineutrophil Cytoplasmic AntibodiesAntinuclear Antibody PositivityAutoantibodies In Rheumatic DiseaseEnzyme-linked Immunosorbent Assay (Elisa)Pathogenic AutoantibodiesSystemic Autoimmune Disease Association
OBJECTIVES: The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19. METHODS: The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA). RESULTS: The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01). CONCLUSION: Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
33
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Multiple early factors anticipate post-acute COVID-19 sequelae
Yapeng Su, Dan Yuan, Daniel Chen et al. · Cell · 2022 · 1.2K citations · Full text
Diverse functional autoantibodies in patients with COVID-19
Eric Y. Wang, Tianyang Mao, Jon Klein et al. · Nature · 2021 · 984 citations · Full text